Abstract: The invention described herein is a method for manufacturing a zinc compound lozenge, comprising the steps of adding at least one form of glycine and at least one form of ionic zinc salt to deionized water forming a zinc-glycine mixture; heating the zinc-glycine mixture to a first temperature; heating a stock base material to at least it's melting point; stirring in the zinc-glycine mixture to the stock base material; adding at least one flavor concentrate while stirring thoroughly to create a final mixture; pouring the final mixture into a mold specifying a final shape of the zinc compound lozenge; and cooling the final mixture in the mold until solid.
Abstract: The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.
Abstract: A medicinal composition for total body detoxification is administered to a user to remove toxins from the user's body, as well as, provide hangover relief subsequent to the consumption of alcoholic beverages. The medicinal composition includes a quantity of activated charcoal and a quantity of dietary supplements; the quantity of activated charcoal and the quantity of dietary supplements being heterogeneously mixed into an orally-administrable composition. The orally-administrable composition is consumed twice a day or proportionally to the quantity of alcohol consumed. The quantity of activated charcoal binds to toxins during digestion to prevent the uptake of the toxins into the user's body. The quantity of dietary supplements replenishes beneficial nutrients to the user.
Abstract: Compositions comprising therapeutically effective amounts of lamellar bodies to restore lubricity and non-stick properties to mucous surfaces for conditions characterised by dry adherent surfaces, particularly those surfaces close to the body openings and conditions of the eye.
Abstract: A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nsPEF). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells. Treated tumor cells from the biopsy are then reintroduced into the subject. The calreticulin-exhibiting tumor cells activate the subject's immune system against the tumor, and any other like tumors in the body, and effectively vaccinates the subject against the disease. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. The immune response may be measured at a later time. Specific electrical characteristics of the nsPEF treatments can be based on the type and/or strength of the tumor.
Type:
Application
Filed:
January 17, 2018
Publication date:
June 7, 2018
Applicant:
Pulse Biosciences, Inc.
Inventors:
Richard Lee Nuccitelli, Pamela S. Nuccitelli, Joanne Lum, Kaying Lui, Brian G. Athos, Mark P. Kreis, Zachary R. Mallon, Jon Berridge
Abstract: Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of NK cells, wherein the antibody binds an antigen on the surface of the NK cells and the antibody binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell now binding the antibody via R-ADCC.
Type:
Application
Filed:
November 24, 2015
Publication date:
June 7, 2018
Inventors:
Armand KEATING, Brent Allen WILLIAMS, Xing-Hua WANG
Abstract: This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
Type:
Application
Filed:
December 1, 2017
Publication date:
June 7, 2018
Inventors:
Brian Curtis Turner, Yosef Refaeli, Gregory Alan Bird
Abstract: The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.
Type:
Application
Filed:
May 27, 2016
Publication date:
June 7, 2018
Inventors:
Veerle BLOEMEN, Johanna BOLANDER, Frank LUYTEN
Abstract: Disclosed herein are methods for generating SC-? cells, and isolated populations of SC-? cells for use in various applications, such as cell therapy.
Abstract: Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of use the bacterial minicells and pharmaceutical compositions.
Abstract: This application provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments, and methods for making, storing and using them, including storage, including long term storage, at ambient temperature. Compositions provided herein are useful for treating various diseases or conditions such as autism spectrum disorder, Crohn's Disease, ulcerative colitis, irritable bowel syndrome, and recurrent or primary C. difficile infection.
Abstract: Provided herein is a method for determining the relative abundance of total bacterial in a sample. Optionally, the method also includes determining whether the subject has a risk of bloodstream infection after chemotherapy, such as a chemotherapy used to prepare a subject for a hematopoietic stem cell transplantation procedure. The method includes determining the relative abundances of bacteria that are described herein as correlating with developing a bloodstream infection after chemotherapy, and determining the relative abundances of bacteria that are described herein as correlating with not developing a bloodstream infection after chemotherapy. Also provided is a composition including a mixture of isolated bacteria and a pharmaceutically acceptable carrier, where the bacteria correlate with not developing a bloodstream infection after chemotherapy.
Abstract: The invention relates to recombinant vaccines capable of presenting all, or antigenic portions of, the Eimeria tenella 3-1e, or profilin. Also provided are methodologies of using the vaccines for oral administration to poultry and other targets in the control of coccidiosis. In particular embodiments, recombinant host cells, such as E. coli, expressing all or part of the 3-1e antigen, are provided that can be used as whole-cell vaccines. In some instances, the native 3-1e protein utilized in the vaccines presented herein is molecularly manipulated.
Type:
Application
Filed:
December 1, 2017
Publication date:
June 7, 2018
Inventors:
HYUN S. LILLEHOJ, WOOHYUN KIM, CHRIS PRZYBYSZEWSKI, D.STEVEN ZATECHKA, JR.
Abstract: The present invention relates to oncolytic adenoviruses with functional deletions of immunodominant T-cell epitopes of adenovirus proteins, as well as to methods of using the oncolytic adenoviruses for the treatment of diseases, such as cancer. The oncolytic adenoviruses may also contain one or more heterologous nucleic acid sequences each encoding a tumor antigen or epitope. The oncolytic adenoviruses may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
Abstract: The present invention relates to a dietary supplement or pharmaceutical composition, comprising lyophylized Saccharomyces boulardii as an active ingredient and as sole probiotic, optionally in association with a pharmaceutically acceptable vehicle, wherein the composition is in a closed vial a having a first airtight compartment comprising lyophilized S. boulardii powder, and a second compartment comprising a solution, wherein the first and second compartment can be brought in airtight communication with one another to yield a suspension of S. boulardii to be administered to an individual upon opening of the vial.
Type:
Application
Filed:
June 11, 2015
Publication date:
June 7, 2018
Inventors:
Jean-Marie LEFEVRE, Gilles RENAUD, Marie-Emmanuelle LE GUERN
Abstract: A pharmaceutical composition comprises a Quisaqualis indica extract as an active ingredient, for preventing or treating prostatic hyperplasia, and may also be used in a food composition. The Quisaqualis indica extract may be used to treat and prevent prostatic hyperplasia by exhibiting effects of a reduction in prostate weight, a reduction in DHT as a prostatic hyperplasia inducing factor, and a reduction in prostate epithelial cell hyperplasia.
Type:
Application
Filed:
May 3, 2016
Publication date:
June 7, 2018
Applicant:
The Industry & Academic Cooperation in Chungnam National University (IAC)
Abstract: A method for stimulating or enhancing the immune system with a composition that includes a Eurycoma longifolia aqueous extract. Also provided is a method for reducing the risk of infectious disease by administering the composition. Further disclosed is a method for treating an individual with a Eurycoma longifolia aqueous extract to increase the number of T-cells, improve Scoring of Immunological Vigor, lower immunological age, reduce fatigue, or alleviate or reduce stress.
Type:
Application
Filed:
December 15, 2017
Publication date:
June 7, 2018
Inventors:
Annie George, Yuuki Kawasaki, Azreena Abas
Abstract: This disclosure relates to methods of inducing adipocyte browning, supporting metabolic flexibility, and/or reducing detrimental WAT deposition or reducing WAT dysfunction in a subject by administering extensively hydrolyzed casein and/or fractions thereof (“eHC”) to the subject, and/or by administering a long chain polyunsaturated fatty acid (e.g., docosahexaenoic acid and/or arachidonic acid) to the subject.
Type:
Application
Filed:
December 5, 2016
Publication date:
June 7, 2018
Inventors:
Yan Zhong, Marieke H. Schoemaker, Teartse Tim Lambers, Eric A.F. van Tol
Abstract: Provided herein are, inter alia, compositions and methods for the treatment of cancer and inhibition of metastasis. The compositions include a ?-opioid receptor (MOR) polypeptide and a somatostatin receptor 2 (SSTR2) polypeptide, wherein the MOR polypeptide is bound to a MOR antagonist and the SSTR2 polypeptide is bound to a SSTR2 antagonist. The compositions and methods provided herein are, inter alia, useful to treat pancreatic cancer.
Abstract: Absorbent structures for absorbent articles are provided, comprising an absorbent layer with absorbent material containing superabsorbent polymer particles supported by a supporting sheet, and having first and a second substantially longitudinal channel that are free of said superabsorbent polymeric particles, and that comprises one or more adhesive material to immobilize said absorbent material. The channels can provide improved fit and/or liquid acquisition/transportation, and/or improved performance.
Type:
Application
Filed:
February 2, 2018
Publication date:
June 7, 2018
Inventors:
Rodrigo ROSATI, Carsten Heinrich KREUZER, Hans Adolf JACKELS, Blanca ARIZTI, Ernesto G. BIANCHI, Donald Carroll ROE
Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
Type:
Application
Filed:
January 8, 2018
Publication date:
June 7, 2018
Inventors:
Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
Abstract: A hydrogel (I), comprising a polymer backbone wherein an aqueous solution of the hydrogel comprises a first lower critical solution temperature, and wherein the hydrogel is configured to be converted in vivo into a modified hydrogel, and wherein an aqueous solution of the modified hydrogel comprises a second lower critical solution temperature, and wherein the second lower critical solution temperature is greater than the first lower critical solution temperature.
Type:
Application
Filed:
December 13, 2017
Publication date:
June 7, 2018
Inventors:
Derek Overstreet, Brent Vernon, Ryan McLemore, Alex McLaren
Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.
Type:
Application
Filed:
November 3, 2017
Publication date:
June 7, 2018
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Venkata-Rangarao KANIKANTI, Petra LANGE, Hans-Juergen HAMANN, Peter KLEINEBUDDE
Abstract: The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.
Type:
Application
Filed:
January 29, 2018
Publication date:
June 7, 2018
Inventors:
Hans Georg Fliri, Rhonan Lee Ford, Antonio Kuok Keong Vong
Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.
Type:
Application
Filed:
April 5, 2016
Publication date:
June 7, 2018
Applicants:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M EDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN, UNIVERSITÉ DE ROUEN, TARGEDYS
Inventors:
Sergueï Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert
Abstract: An object of the present invention is the use of Irisin for the treatment and/or prevention of osteoporosis. In particular, the present invention refers to the use of recombinant irisin for the treatment and/or prevention of osteoporosis. A method for preventing and/or treating osteoporosis by administering an effective amount of irisin to a subject, is provided.
Type:
Application
Filed:
January 26, 2018
Publication date:
June 7, 2018
Inventors:
Maria GRANO, Graziana COLAIANNI, Concetta CUSCITO, Giacomina BRUNETTI, Silvia COLUCCI, Saverio CINTI, Giorgio MORI
Abstract: Provided is a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1h, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.
Type:
Application
Filed:
May 4, 2016
Publication date:
June 7, 2018
Applicant:
SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION
Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
Type:
Application
Filed:
May 20, 2016
Publication date:
June 7, 2018
Inventors:
Thierry LEVEILLARD, John FLANNERY, Mei XIN, Leah BYRNE, José-Alain SAHEL, Emmanuelle CLERIN-LACHAPELLE, Sun JUNWEI, Jean BENNETT, Jeannette BENNICELLI
Abstract: Compositions and surgical methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.
Abstract: Provided are a pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia including glucagon-like peptide-1 (GLP-1), a GLP-1 fragment, a GLP-1 secretion enhancer, a GLP-1 degradation inhibitor, a GLP-1 receptor (GLP-1R) agonist, or exendin-4, and a method of treating muscle atrophy or sarcopenia by using the pharmaceutical composition. When the pharmaceutical composition for preventing or treating muscle atrophy or sarcopenia provided in the present invention is administered to a subject having sarcopenia or muscle atrophy, reduced body weight, skeletal muscle mass, and grip strength, which are caused by sarcopenia or muscle atrophy, and expression levels of genes involved in muscle production may be restored to normal states, and therefore, the composition may be widely applied to the development of effective therapeutic agents for sarcopenia or muscle atrophy.
Type:
Application
Filed:
May 27, 2016
Publication date:
June 7, 2018
Inventors:
Hee Sook JUN, Eun Young PARK, Yeon Hee HONG
Abstract: The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
Type:
Application
Filed:
October 3, 2017
Publication date:
June 7, 2018
Inventors:
Carl Spana, John H. Dodd, Marie Makhlina
Abstract: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.
Abstract: A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size d50 in the range 0.1-2 ?m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size d50 in the range of more than 0.5 and up to 5 ?m.
Type:
Application
Filed:
June 6, 2016
Publication date:
June 7, 2018
Applicant:
Evonik Roehm GmbH
Inventors:
Juan Tome-Alcalde, Norbert Windhab, Melanie Liefke, Anne Benedikt, Jessica Müller-Albers, Tom Tice, Susanne Ullrich, Andrea Engel, Matthias Germer, Steffen Kistner, Jens Daufenbach
Abstract: The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.
Type:
Application
Filed:
May 20, 2016
Publication date:
June 7, 2018
Inventors:
Stefan SCHULTE, Hans-Wilhelm BELTZ, Sabine PESTEL, Thomas WEIMER, Matthias PELZING
Abstract: The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.
Abstract: The invention relates to compositions comprising Pinus pinaster stem bark extract, papain, and Aloe vera extract, and methods of manufacturing same. There are also described methods of treating or preventing a variety of conditions, including treating or preventing elevated blood glucose, pre-diabetes, type 2 diabetes, autoimmune diseases, reducing or decreasing inflammation, treating or preventing diseases characterised by elevated levels of inflammation, and lowering blood cholesterol, said methods comprising administering an effective amount of a composition according to the invention to a subject in need thereof. Uses of the composition of the invention for the manufacture of a medicament for treating or preventing a variety of conditions are also described.
Type:
Application
Filed:
July 14, 2015
Publication date:
June 7, 2018
Applicant:
Arborvitae Health and Wellbeing Pty. Ltd.
Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
Type:
Application
Filed:
July 17, 2017
Publication date:
June 7, 2018
Inventors:
Elliott A. GRUSKIN, Jack L. TSENG, Anthony O. CAGGIANO
Abstract: An object of the present invention is to provide a vaccine that can simultaneously reduce A? deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-?, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.
Abstract: The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor T cells (CAR T cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (TKI), or an adoptively transferred cells incorporating engineered T cell receptors, and a live attenuated recombinant Listeria strain comprising a fusion protein of a Truncated LLO, a truncated ActA or a PEST-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment.
Type:
Application
Filed:
December 18, 2015
Publication date:
June 7, 2018
Inventors:
Robert Petit, Anu Wallecha, Yvonne Patterson, Reshma Singh
Abstract: Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an HLA protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to HLA proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.
Type:
Application
Filed:
May 20, 2016
Publication date:
June 7, 2018
Inventors:
Edward F. Fritsch, Nir Hacohen, Michael S. Rooney, Sachet Ashok Shukla, Catherine J. Wu, Pavan Bachireddy, Jing Sun
Abstract: The present invention relates to an attenuated strain of Salmonella comprising a DNA molecule encoding CMV pp65. In particular, the present invention relates to the use of said attenuated strain of Salmonella in cancer immunotherapy.
Abstract: Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.
Type:
Application
Filed:
January 22, 2018
Publication date:
June 7, 2018
Inventors:
Zhao Wu, Zhigang Liu, Lei Xiao, Chengfei Pu, Zhiyuan Cao
Abstract: A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.
Type:
Application
Filed:
February 2, 2018
Publication date:
June 7, 2018
Applicants:
The Board of Regents of the University of Texas System, Yale University, The United States of America, as represented by the Secretary, Department of Health and Human Serv
Inventors:
Chandrashekhar PASARE, Scott N. FURLAN, Noah W. PALM, Arun UNNI
Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
Type:
Application
Filed:
November 1, 2017
Publication date:
June 7, 2018
Applicant:
GenVec, Inc.
Inventors:
Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
Type:
Application
Filed:
October 11, 2017
Publication date:
June 7, 2018
Applicant:
The University of Tokyo
Inventors:
Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.